Sondrel (Holdings) plc, the fabless semiconductor business providing turnkey services in the design and delivery of ‘application specific integrated circuits’ (“ASICs”) and ‘system on chips’ (“SoCs”) for leading global technology
AstraZeneca Abandons The Pledge Of Not-For Profit Made During The Pandemic
AstraZeneca has decided to abandon the pledge of not-for profit made during the pandemic and aims to make a modest profit from COVID-19 vaccinations.
The highs and lows of drug launches
Every drug has its beneficiaries, whether they are suffering from a common chronic disease, a more severe form of cancer or a rare condition that affects 1 in 10,000 people. However,
Are Deepmatter Double Reporting By Announcing Trials with Dr Reddys and a Subsidiary ?
DeepMatter Group PLC today announced it has signed a contract to trial its DigitalGlassware® platform with Aurigene Pharmaceutical Services based in Hyderabad, India, to supply its DigitalGlassware® platform.
Deepmatter Competitor PathAI Welcomed by Roche into its open digital pathology initiative
Roche has selected PathAI to collaborate with it on an artificial intelligence program that will be merged with its digital pathology work.
The rise of robots and automation in the Chemistry Lab
Automated chemistry has been a priority for many companies since the outbreak of the pandemic. Paul Whittles is the sales director at Deepmatter Group (a company based in Glasgow, UK
Major advances in science and life sciences from Welsh Companies and Universities
Science in Wales is booming, photonics company Sulis Technology and Imperial College London passed phase 1 human trials for a cancer detection system where a flurofore is added to the body